The Training and Education Core will 1) provide direct support and a specialized training program for one pre-doctoral and one postdoctoral trainee;2) provide comprehensive training in muscular dystrophy for all Center participants;and 3) support outreach for education of patients, their families, and physicians in the community. The participating faculty are experienced clinicians and basic scientists intensively involved in education with a history of collaborative interactions. The training pool is composed of a comprehensive set of high-caliber clinical programs and Ph.D. graduate programs at the Ohio State University and Nationwide Children's Hospital. Clinical and basic science trainees will actively participate in a research project aligned with the translational goals of the MDCRC. Basic science trainees will have the opportunity to attend the muscular dystrophy and its ancillary clinics. Coursework that fosters translational research and instruction in the responsible conduct of research will be required for all trainees supported by this core. This cross-discipline training model will be further enriched for all predoctoral and postdoctoral trainees and junior faculty by support of the ongoing Nationwide Children's Hospital and OSU Muscle Study Group. Center participants will also be actively involved in educating patients, their families, local physicians and high school students about research advances in muscular dystrophy. This core will therefore provide comprehensive training required to foster the careers of future generations of clinicians and scientists in the field of muscular dystrophy.

Public Health Relevance

This core will provide training and education for one pre-doctoral and one post-doctoral student each year. The training will be focused around developing comprehensive researchers in muscular dystrophy that combines studies at both the basic and clinical levels.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nationwide Children's Hospital
United States
Zip Code
Mendell, Jerry R; Sahenk, Zarife; Malik, Vinod et al. (2015) A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 23:192-201
Heller, Kristin N; Montgomery, Chrystal L; Shontz, Kimberly M et al. (2015) Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice. Hum Gene Ther 26:647-56
Chicoine, L G; Montgomery, C L; Bremer, W G et al. (2014) Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 22:338-47
Mendell, Jerry R; Lloyd-Puryear, Michele (2013) Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 48:21-6
Flanigan, Kevin M; Campbell, Katie; Viollet, Laurence et al. (2013) Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24:797-806
Rodino-Klapac, Louise R; Mendell, Jerry R; Sahenk, Zarife (2013) Update on the treatment of Duchenne muscular dystrophy. Curr Neurol Neurosci Rep 13:332
Heller, Kristin N; Montgomery, Chrystal L; Janssen, Paul Ml et al. (2013) AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice. Mol Ther 21:520-5
Mendell, Jerry R; Shilling, Chris; Leslie, Nancy D et al. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71:304-13
Mendell, Jerry R; Rodino-Klapac, Louise; Sahenk, Zarife et al. (2012) Gene therapy for muscular dystrophy: lessons learned and path forward. Neurosci Lett 527:90-9